Silexion Therapeutics LTD (SLXN)
1.01
-0.02 (-1.94%)
At close: Apr 24, 2025, 12:00 PM
-1.94% (1D)
| Bid | 0.96 |
| Market Cap | 8.78M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -16.44M |
| EPS (ttm) | -39.75 |
| PE Ratio (ttm) | -0.03 |
| Forward PE | -0.6 |
| Analyst | Buy |
| Ask | 1.06 |
| Volume | 1,446,869 |
| Avg. Volume (20D) | 14,707,749 |
| Open | 0.97 |
| Previous Close | 1.03 |
| Day's Range | 0.86 - 1.01 |
| 52-Week Range | 0.21 - 13.56 |
| Beta | 0.06 |
About SLXN
Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, ...
Industry Biotechnology
Sector Healthcare
IPO Date Aug 16, 2024
Employees NaN
Stock Exchange NASDAQ
Ticker Symbol SLXN
Website https://silexion.com
Analyst Forecast
According to 1 analyst ratings, the average rating for SLXN stock is "Buy." The 12-month stock price forecast is $5, which is an increase of 394.80% from the latest price.
Stock Forecasts1 day ago
+46.51%
Sliexion Therapeutics shares are trading higher af...
Unlock content with
Pro Subscription
1 month ago
+30.63%
Silexion Therapeutics shares are trading higher after the company announced groundbreaking initial data from its systemic administration of SIL204 in orthotopic pancreatic cancer models.
